BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events

ME Staff 8-k
-
0

BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01Other Events.

On December 9, 2017, BeiGene, Ltd. (the “Company”) issued a press release announcing updated preliminary clinical data from an ongoing Phase 1b trial of its investigational Bruton’s Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) in combination with the anti-CD20 antibody GAZYVA® (obinutuzumab) in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma and follicular lymphoma, presented at the 59thAmerican Society of HematologyAnnual Meeting inAtlanta, GA (“ASH”). Thefull text of this press release is filed as Exhibit 99.1to this Current Report on Form 8-K and is incorporated herein byreference.

On December 9, 2017, the Company issued a press release announcingpreliminary clinical data from an ongoing Phase 1b trial of its investigational BTK inhibitor zanubrutinib (BGB-3111) in patients with non-Hodgkin’s lymphoma, presented at ASH. Thefull text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein byreference.

On December 11, 2017, the Company issued a press release announcinginitial data from the ongoing Phase 1b trial of its investigational BTK inhibitor, zanubrutinib (BGB-3111), in combination with its investigational anti-PD-1 antibody, tislelizumab (BGB-A317), in patients with B-cell malignancies, presented at ASH. Thefull text of this press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein byreference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release titled “BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting,” issued on December 9, 2017

99.2

Press Release titled “BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting,” issued on December9, 2017

99.3

Press Release titled “BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting,” issued on December 11, 2017


BeiGene, Ltd. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.1 – BGB-3111 GAZYVA Exhibit 99.1                                 BeiGene,…
To view the full exhibit click here

About BEIGENE,LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.